drugset / Trial / NCT04788615
Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS
RandomizedParallel-groupSingle-blindTreatment
Summary
This study will compare ofatumumab vs. European approved platform first line self-administered disease modifying therapy (DMT) in newly diagnosed MS patients
Timeline
- Start
- 2021-07-23
- Primary completion
- 2025-11-04
- Completion
- 2025-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Diroximel fumarate | Small molecule | 231 mg | — |
| Comparator | Diroximel fumarate | Small molecule | 462 mg | — |
| Comparator | Glatiramer Acetate | Small molecule | 20 mg | — |
| Comparator | Glatiramer Acetate | Small molecule | 40 mg | — |
| Subject | Ofatumumab | Monoclonal antibody | 20 mg | Subcutaneous |
| Comparator | Teriflunomide | Small molecule | 14 mg | — |
| Comparator | dimethyl fumarate | Unknown | 120 mg | — |
| Comparator | dimethyl fumarate | Unknown | 240 mg | — |
| Comparator | peginterferon beta-1a | Protein / enzyme biologic | 63 ug | — |
| Comparator | peginterferon beta-1a | Protein / enzyme biologic | 125 ug | — |